Electroporation can sometimes lead to issues like tonic signaling or faulty CAR function. PTX’s pursuit of a low-cost, non-viral method for CAR-T manufacturing may have contributed to this tonic signaling. However, OmniCAR’s switchable system is designed for precise control, and by resolving these issues through protein engineering, PTX has ensured the platform can prevent unintended activation and work reliably, even in complex manufacturing settings. And if we can get the therapy right for large scale manufacturing now will be game changing due to most car t therapies in the clinic today are not built for scalability so it will give us an competitive advantage
PTX Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
